NATRIURETIC PEPTIDE SYSTEM IN HUMAN HEART-FAILURE

被引:369
|
作者
WEI, CM
HEUBLEIN, DM
PERRELLA, MA
LERMAN, A
RODEHEFFER, RJ
MCGREGOR, CGA
EDWARDS, WD
SCHAFF, HV
BURNETT, JC
机构
[1] MAYO CLIN & MAYO FDN, DIV CARDIOVASC SURG, ROCHESTER, MN 55905 USA
[2] MAYO CLIN & MAYO FDN, DEPT PHYSIOL & BIOPHYS, ROCHESTER, MN 55905 USA
关键词
NATRIURETIC PEPTIDES; HEART FAILURE; LEFT VENTRICLE;
D O I
10.1161/01.CIR.88.3.1004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) are a family of structurally related peptides that participate in the integrated control of renal and cardiovascular function. Previous studies suggest a functional role for these hormonal peptides in cardiorenal regulation in congestive heart failure (CHF). Methods and Results. The present studies were performed in normal subjects (n=6) and in patients with mild (New York Heart Association [NYHA] class I to II, n=20) and severe (NYHA class III to IV, n=20) CHF by use of radioimmunoassay and immunohistochemical staining (IHCS). Plasma ANP was significantly increased in both mild and severe CHF compared with normal subjects. In contrast, plasma BNP was only moderately increased in the severe CHF group, and plasma CNP concentration was unchanged in CHF compared with normal subjects. Atrial tissue concentrations of the natriuretic peptides did not parallel circulating concentrations. ANP predominated in normal atrial tissue, but BNP predominated in CHF. In ventricular tissue, IHCS staining was present for all three peptides in normal ventricular myocardium and was markedly enhanced in CHF. Conclusions. These studies support,a differential regulation of ANP, BNP, and CNP circulating concentrations and tissue activity in human CHF.
引用
收藏
页码:1004 / 1009
页数:6
相关论文
共 50 条
  • [1] Natriuretic peptide system is not exhausted in severe heart failure
    Lourenco, Patricia
    Azevedo, Ana
    Araujo, Jose Paulo
    Bettencourt, Paulo
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2009, 10 (01) : 39 - 43
  • [2] Pharmacogenomics of the Natriuretic Peptide System in Heart Failure
    Abuzaanona A.
    Lanfear D.
    Current Heart Failure Reports, 2017, 14 (6) : 536 - 542
  • [3] Natriuretic Peptide Testing in Heart Failure
    Kim, Han-Na
    Januzzi, James L., Jr.
    CIRCULATION, 2011, 123 (18) : 2015 - 2019
  • [4] Maximizing the natriuretic peptide system in experimental heart failure - Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition
    Chen, HH
    Lainchbury, JG
    Harty, GJ
    Burnett, JC
    CIRCULATION, 2002, 105 (08) : 999 - 1003
  • [5] Genetic variation in the natriuretic peptide system and heart failure
    David E. Lanfear
    Heart Failure Reviews, 2010, 15 : 219 - 228
  • [6] Genetic variation in the natriuretic peptide system and heart failure
    Lanfear, David E.
    HEART FAILURE REVIEWS, 2010, 15 (03) : 219 - 228
  • [7] Advances in heart failure: natriuretic peptide testing
    Rehman, S. U.
    Januzzi, J. L.
    PANMINERVA MEDICA, 2008, 50 (02) : 139 - 151
  • [8] Natriuretic Peptide Guided Heart Failure Management
    Mohammed, Asim A.
    Januzzi, James L., Jr.
    CURRENT CLINICAL PHARMACOLOGY, 2009, 4 (02): : 87 - 94
  • [9] Neprilysin and Natriuretic Peptide Regulation in Heart Failure
    Bayes-Genis A.
    Morant-Talamante N.
    Lupón J.
    Current Heart Failure Reports, 2016, 13 (4) : 151 - 157
  • [10] VASODILATORY EFFECTS OF C-TYPE NATRIURETIC PEPTIDE ON FOREARM RESISTANCE VESSELS ARE DISTINCT FROM THOSE OF ATRIAL-NATRIURETIC-PEPTIDE IN CHRONIC HEART-FAILURE
    NAKAMURA, M
    ARAKAWA, N
    YOSHIDA, H
    MAKITA, S
    HIRAMORI, K
    CIRCULATION, 1994, 90 (03) : 1210 - 1214